Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023387 · ClinicalTrials.gov registry record · NA
TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine
A NA study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT00023387 is a NA study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 36 participants.
The verdict
NCT00023387, a NA study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
Primary objective: To compare the pharmacokinetics of rifapentine and 25-desacetyl rifapentine at three different doses: 600 mg, 900 mg, and 1200 mg. Secondary objective: To describe any correlation between pharmacokinetic parameters of three different doses of rifapentine plus a standard dose of isoniazid and the occurrence of toxicity attributed to anti-tuberculosis treatment.
Interventions
- DRUG Isoniazid
- DRUG Rifapentine
- DRUG 25-desacetyl Rifapentine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2000-03 |
| Est. Completion | 2001-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00023387
The ClinicalTrials.gov registry entry for NCT00023387 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Isoniazid is the first listed.
NCT00023387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00023387 about?
NCT00023387 is a clinical study titled "TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine". Primary objective: To compare the pharmacokinetics of rifapentine and 25-desacetyl rifapentine at three different doses: 600 mg, 900 mg, and 1200 mg. Secondary objective: To describe any correlation between pharmacokinetic parameters of three different doses of rifapentine plus a standard dose of i...
What is the current status of trial NCT00023387?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2000-03. Estimated completion is 2001-05.
What interventions are being tested in trial NCT00023387?
The interventions under investigation include: Isoniazid (DRUG), Rifapentine (DRUG), 25-desacetyl Rifapentine (DRUG).
Who is sponsoring clinical trial NCT00023387?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.